Evaluation of the SLOMYCO Sensititre (R) panel for testing the antimicrobial susceptibility of Mycobacterium marinum isolates by Chazel, M. et al.
Chazel et al. Ann Clin Microbiol Antimicrob  (2016) 15:30 
DOI 10.1186/s12941-016-0145-1
RESEARCH
Evaluation of the SLOMYCO Sensititre® 
panel for testing the antimicrobial susceptibility 
of Mycobacterium marinum isolates
Marion Chazel1, Hélène Marchandin1,2, Nicolas Keck3, Dominique Terru1, Christian Carrière1,5,6, 
Michael Ponsoda4, Véronique Jacomo4, Gilles Panteix4, Nicolas Bouzinbi1, Anne‑Laure Bañuls7, Marc Choisy7, 
Jérôme Solassol6,8,9, Alexandra Aubry10,11,12,13† and Sylvain Godreuil1,5,6*†
Abstract 
Background: The agar dilution method is currently considered as the reference method for Mycobacterium marinum 
drug susceptibility testing (DST). As it is time‑consuming, alternative methods, such as the E‑test, were evaluated for 
M. marinum DST, but without success. The SLOMYCO Sensititre® panel, recently commercialized by TREK Diagnostic 
Systems (Cleveland, OH), can be used for DST in slow‑growing mycobacteria and for antimicrobial agents recom‑
mended by the Clinical and Laboratory Standards Institute (CLSI) for M. marinum DST. The main goal of this work was 
to evaluate the SLOMYCO Sensititre® panel method for DST in M. marinum isolates from human patients and fish rela‑
tive to the reference agar dilution method.
Methods/Results: The reproducibility of the minimum inhibitory concentration (MIC) determination (±1 log2 
dilution) was very good for both the agar dilution method and SLOMYCO Sensititre® panel (>90 % agreement). The 
percentage essential agreement between methods varied, depending on the drug: between 97 and 75 % for cipro‑
floxacin, moxifloxacin, linezolid, isoniazid, clarithromycin, amikacin, rifabutin and rifampin, 74 % for trimethoprim, 72 % 
for doxycycline, 70 % for sulfamethoxazole, 59 % for streptomycin, 33 % for ethambutol and only 2.2 % for ethiona‑
mide. When the agar dilution and SLOMYCO Sensititre® panel results were converted into interpretive criteria, the 
category agreement was 100 % for amikacin, ciprofloxacin, clarithromycin, moxifloxacin, rifabutin, sulfamethoxazole 
and trimethoprim, 98 % for ethambutol and 96 % for rifampin and no agreement for doxycycline.
Conclusions: The SLOMYCO Sensititre® panel method could provide a potential alternative to the reference agar 
dilution method, when DST in M. marinum is required, except for doxycycline.
Keywords: Mycobacterium marinum, SLOMYCO Sensititre® panel, Agar dilution method, Antimicrobial susceptibility 
testing, Human and fish isolates
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Background
Mycobacterium marinum, a slow-growing nontubercu-
lous photochromogenic mycobacteria, is an ubiquitous 
waterborne organism [9, 10, 17] that causes diseases 
in many fish species from cold or warm, fresh or salted 
water, and also in many other aquatic animals, such as 
amphibians, mammals and oysters [9, 10, 17]. In humans, 
M. marinum infection is commonly limited to the skin, 
but it can spread to deeper structures, resulting in teno-
synovitis, arthritis and osteomyelitis [1, 8, 13] and, rarely, 
in disseminated infection in immunocompromised 
patients [13].
Mycobacterium marinum is naturally multi-drug resist-
ant and there is no standardized antimicrobial treat-
ment for M. marinum infections [7]. As the wild-type 
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susceptibility pattern of M. marinum is well known [2] 
and acquired resistance has not been described so far, 
antimicrobial susceptibility testing is not recommended 
except in the case of treatment failure and relapse [16].
The Clinical and Laboratory Standards Institute (CLSI) 
recommends microdilution for M. marinum drug suscep-
tibility testing (DST) [16], but the agar dilution method 
is currently considered to be the reference method [2, 4, 
19]. As this method is time-consuming, alternative meth-
ods, such as the E-test, were evaluated, but showed poor 
agreement with the reference method and therefore are 
not suitable for DST in M. marinum [2, 11, 19]. Recently, 
the SLOMYCO Sensititre® panel was commercialized by 
TREK Diagnostic Systems (Cleveland, OH) [3]. This is a 
standard-order broth microdilution panel that can be 
used to evaluate the susceptibility of slow growing myco-
bacteria to 14 antimicrobial agents, including those rec-
ommended by CLSI for M. marinum DST [3].
The main goal of this work was to evaluate the SLO-
MYCO Sensititre® panel method for DST in M. marinum 
strains from humans and fish relative to the reference 
agar dilution method.
Methods
Bacterial strains and growth conditions
The origin and other information concerning the tested 
M. marinum isolates are described in Broutin et  al. [5]. 
The 35 M. marinum isolates from human patients and 
nine from fish were collected in France between 1995 and 
2007. None was from patients who experienced treat-
ment failure or relapse. M. marinum identification was 
performed using GenoType Mycobacterium AS/CM, a 
commercial multiplex line-probe assay (Hain Lifesci-
ence GmbH, Nehren, Germany). Isolates were stored at 
−80 °C in Middlebrook 7H9 broth (DIFCO, Detroit, MI, 
USA) containing 5 % OADC (DIFCO, Detroit, MI, USA) 
until determination of the Minimum inhibitory con-
centrations (MICs). Mycobacteria were then cultured 
in Löwenstein-Jensen (LJ) slants (bioMérieux, Marcy 
l’Etoile, France) and in Middlebrook 7H10 agar (DIFCO, 
Detroit, MI, USA). The M. marinum ATCC 927 strain 
(from fish) and the M. marinum ATCC BAA-535/M 
strain isolated from an infected patient were used as con-
trols for MIC determination.
Antimicrobial agents
Amikacin, ciprofloxacin, clarithromycin, doxycycline, 
ethambutol, ethionamide, isoniazid, rifampin, rifabu-
tin, streptomycin and trimethoprim (Sigma-Aldrich, 
Lyon, France), linezolid (Pfizer, France) and moxifloxa-
cin (Bayer, Wuppertal, Germany) were tested in this 
study. Stock solutions of each drug were prepared using 
the appropriate solvent and were filter-sterilized before 
storage at −80 °C. To prior testing, each drug was freshly 
diluted in sterile deionized water. The concentration 
ranges of the tested antimicrobial agents are indicated in 
Table 1.
MIC determination by using the agar dilution method
The agar dilution method was performed on Müller-
Hinton agar (Becton–Dickinson, France) supplemented 
with 5  % OADC according to CLSI [16]. Twofold dilu-
tions of the antibiotics to be tested were added to obtain 
the required final concentrations. Confluent colonies of 
the different bacteria in LJ slants were swept with a loop 
and emulsified in sterile water and the concentration 
was adjusted to the McFarland n. 1 standard turbidity. A 
1/100 dilution of each suspension adjusted to the McFar-
land n. 1 standard was inoculated using a Steers replica-
tor to deliver approximately 104 colony-forming units 
(CFU) per spot. Plates were incubated at 30 °C [16]. The 
MICs (i.e., the lowest concentration of antibiotic result-
ing in complete inhibition of growth) of the tested anti-
biotics were determined after 7 and 14 days of growth of 
the different M. marinum isolates/controls.
MIC determination using the SLOMYCO Sensititre® panel 
(broth micro‑dilution method)
Inocula for the SLOMYCO Sensititre® panel were pre-
pared according to the CLSI and the manufacturer’s 
instructions [16]. SLOMYCO plates were incubated in 
a non-CO2 incubator at 30 °C until the controls showed 
sufficient growth (7–14  days). The MICs were deter-
mined visually using an inverted mirror and read as the 
lowest concentration of the antibiotic showing 100  % 
growth inhibition.
Analysis of the results
The reproducibility of both methods was evaluated by 
performing two independent tests for each method and 
for each of the 44 isolates (a total of 176 tests) and five 
independent tests for the M. marinum ATCC 927 and 
ATCC BAA-535/M strains (a total of 30 tests). Each test 
result was independently interpreted by two blinded 
readers. The reproducibility value was defined as the per-
centage of strains with the same MIC value ±1 log2 dilu-
tion at each test. The essential agreement between the 
agar dilution and SLOMYCO Sensititre® panel results 
was expressed as the percentage of isolates that showed 
the same MIC value ±1 log2 dilution with the two meth-
ods. Category agreement was evaluated using the break-
points for determining the susceptibility and resistance 
categories recommended by CLSI [16]. For this study 
only very major errors (i.e., an isolate resistant [R] by 
the reference method, but susceptible [S] by the tested 
method) and major errors (S by the reference method 
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and R by the test method) were considered. Minor errors 
(intermediate [I] by one method and S or R by the other 
method) were not considered because the CLSI break-
points allow only two characterization categories (R or S) 
[16].
Results
The reproducibility of the results obtained with the 
agar dilution method (reference method) was very good 
(Table 2) for all antibiotics. The MICs of the 14 antimicro-
bial agents determined by using the agar dilution method 
were distributed in a narrow range (Table 1). Comparison 
of the MICs for the M. marinum isolates from infected 
humans and fish did not reveal any difference.
The MICs for the two reference M. marinum strains 
(ATCC 927 and ATCC BAA-535/M) were within 0–1 
dilution of the MICs of the 44 tested isolates and within 
the expected range.
The MICs at which 90  % of isolates were inhibited 
(MIC90) of amikacin (4 μg/mL), clarithromycin (2 μg/mL) 
and rifabutin (0.12  μg/mL) were below the CSLI break-
point, whereas the MIC90 of ciprofloxacin (2  μg/mL), 
doxycycline (4 μg/mL), ethambutol (4 μg/mL), moxiflox-
acin (1 μg/mL), rifampin (1 μg/mL) and sulfamethoxazole 
(19 μg/mL) were close to the breakpoint [16]. The MIC90 
of rifampin, rifabutin, moxifloxacin and trimethoprim 
(between 0.1 and 1 μg/mL) were lower than those of the 
other tested antibiotics.
The relatively high MIC90 of ethionamide (10 μg/mL), 
isoniazid (8  μg/mL) and streptomycin (16  μg/mL), for 
which breakpoints are not available, suggests that they 
are not good candidates for the treatment of M. marinum 
infection. In contrast, linezolid (MIC90: 2  μg/mL) was 
very effective against the different M. marinum isolates 
with MIC values among the lowest in our study.
The SLOMYCO Sensititre® panel method (tested 
method) produced remarkably consistent and reproduc-
ible results (Table  3). Reproducibility with this method 
was 100  % in the case of ethionamide, isoniazid, moxi-
floxacin, rifampin, trimethoprim and sulfamethoxazole, 
and between 98 and 87  % for amikacin, ciprofloxacin, 
clarithromycin, doxycycline, ethambutol, linezolid, 
rifabutin and streptomycin (Table  3). The percent-
age essential agreement (±1 log2 dilution) between the 
MICs obtained with the tested and the reference meth-
ods (Table 4) greatly varied depending on the drug: from 
98 % for ciprofloxacin and linezolid to 2.2 % for ethiona-
mide. Good agreement percentages were obtained for 
moxifloxacin (91.3 %), isoniazid (87 %) and clarithromy-
cin (85 %); whereas, agreement was lower for amikacin 
(76.1  %), rifampin (76.1  %), rifampin (76  %), trimetho-
prim (74  %), doxycycline (72  %), sulfamethoxazole 
Table 1 MIC (μg/mL) of  the 14 antibiotics tested in  46 M. marinum isolates (35 clinical, 9 fish and  2 references strains), 
determined by using the agar dilution method
a Concentration range of the tested drugs by using the agar dilution method (ADM) and the SLOMYCO Sensititre® panel method (SSPM): amikacin (0.25–32 mg/L, 
ADM; 1–64 µg/mL, SSPM); ciprofloxacin (0.12–16 µg/mL, ADM, SSPM); clarithromycin (0.06–32 µg/mL, ADM, SSPM); doxycycline (0.12–16 µg/mL, ADM, SSPM); 
ethambutol (0.5–16 µg/mL, ADM, SSPM); ethionamide (0.3–20 µg/mL, ADM, SSPM); isoniazid (0.25–16 µg/mL, ADM; 0.25–8 µg/mL, SSPM); linezolid (0.12–32 µg/mL, 
ADM; SSPM, 1–64 µg/mL); moxifloxacin (0.06–8 µg/mL, ADM; 0.12–8 µg/mL, SSPM); rifabutin (0.06–16 µg/mL, ADM; 0.25–8 mg/L, SSPM); rifampin (0.12–8 mg/L, ADM; 
0.25–8 µg/mL, SSPM); streptomycin (0.5–32 µg/mL, ADM; 0.5–64 µg/mL, SSPM); sulfamethoxazole (2.38–152 µg/mL, ADM, SSPM); trimethoprim (0.12–8 µg/mL, ADM, 
SSPM); NA not available
Antimicrobial agent  
[breakpoints (µg/mL)]a
MIC50 MIC90 Range
Total (n = 46) Human (n = 35) Fish (n = 9) Total (n = 46) Human (n = 35) Fish (n = 9)
Amikacin (>32) 2 2 2 4 4 2 2–4
Ciprofloxacin (>2) 2 2 2 2 2 2 2
Clarithromycin (>16) 2 2 2 2 2 2 1–2
Doxycycline (>4) 4 4 4 4 4 4 1–4
Ethambutol (>4) 2 2 2 4 4 2 1–8
Ethionamide (NA) 5 5 5 10 10 10 2.5–10
Isoniazid (NA) 8 8 8 8 8 8 2–8
Linezolid (NA) 1 1 1 2 2 2 0.5–4
Moxifloxacin (>2) 1 1 1 1 1 1 0.12–1
Rifabutin (>2) 0.12 0.12 0.12 0.12 0.12 0.12 0.12
Rifampin (>1) 0.5 0.5 0.5 1 1 1 0.5–2
Streptomycin (NA) 16 16 16 16 16 16 4–32
Sulfamethoxazole (>38) 9.5 9.5 9.5 19 19 19 4.75–19
Trimethoprim (>2) 0.5 0.5 0.5 1 1 1 0.25–1
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(70 %), streptomycin (59 %) and particularly ethambutol 
(33 %). In the case of ethambutol and ethionamide, the 
SLOMYCO Sensititre® panel method underestimated 
the MICs by 2–3 dilutions compared with the refer-
ence method. When the agar dilution and SLOMYCO 
Sensititre® panel results were converted into inter-
pretive categories (resistance/susceptibility) using the 
CLSI breakpoints, the category agreement was 100  % 
for amikacin, ciprofloxacin, clarithromycin, moxifloxa-
cin, rifabutin and sulfamethoxazole–trimethoprim 
(SMT-TMP), 98 % for ethambutol and 96 % for rifampin 
(Table  5). Two very major discrepancies were observed 
for rifampin (2/46) and one for ethambutol (1/46). No 
agreement was observed between the two methods for 
doxycycline, with 46 (100  %) major discrepancies. The 
SLOMYCO Sensititre® method overestimated the dox-
ycycline MIC by 1 dilution; however, with this method, 
doxycycline MIC90 (8  μg/mL) was close to the suscep-
tibility breakpoint obtained by using the agar dilution 
method (4 μg/mL).
Table 2 Reproducibility of the results (i.e., MIC, expressed in µg/mL, of the tested antibiotics in the 46 M. marinum iso-
lates) obtained with the agar dilution method
Antimicrobial  
agents
No. of results within log2 concentration difference of % agreement  
(confidence interval)
>−2 −2 −1 0 1 2 >2
Amikacin 0 0 0 45 1 0 0 100 (89–100)
Ciprofloxacin 0 0 4 33 7 2 0 96 (84.3–99.3)
Clarithromycin 0 0 10 23 13 0 0 100 (88–99)
Doxycycline 0 0 6 38 1 1 0 98 (87–100)
Ethambutol 0 0 2 43 0 1 0 98 (87–100)
Ethionamide 0 0 7 29 10 0 0 100 (90.4–100)
Isoniazid 0 0 5 21 20 0 0 100 (86–99.3)
Linezolid 0 1 12 20 12 1 0 96 (87–100)
Moxifloxacin 0 0 10 33 3 0 0 100 (90.4–100)
Rifabutin 0 1 3 28 14 0 0 98 (87–100)
Rifampin 0 0 12 30 4 0 0 100 (90.4–100)
Streptomycin 0 1 5 29 11 0 0 98 (87–100)
Sulfamethoxazole 0 0 10 25 11 0 0 100 (90.4–100)
Trimethoprim 0 0 10 26 10 0 0 100 (90.4–100)
Table 3 Reproducibility of the results (i.e., MIC, expressed in µg/mL, of the tested antibiotics in the 46 M. marinum iso-
lates) obtained with the SLOMYCO Sensititre® panel method
Antimicrobial  
agents
No. of results within log2 concentration difference of % agreement  
(confidence interval)
>−2 −2 −1 0 1 2 >2
Amikacin 0 0 0 45 0 1 0 98 (87–100)
Ciprofloxacin 0 1 4 33 7 1 0 96 (84.3–99.3)
Clarithromycin 0 0 10 23 10 3 0 93.5 (81.1–98.3)
Doxycycline 0 0 6 38 1 1 0 97 (87–100)
Ethambutol 0 1 1 43 0 1 0 95.6 (84–99.2)
Ethionamide 0 0 4 29 13 0 0 100 (90.4–100)
Isoniazid 0 0 7 19 20 0 0 100 (86–99.3)
Linezolid 0 1 12 20 12 1 0 96 (87–100)
Moxifloxacin 0 0 7 36 3 0 0 100 (90.4–100)
Rifabutin 0 0 3 28 14 1 0 98 (87–100)
Rifampin 0 0 8 34 4 0 0 100 (90.4–100)
Streptomycin 0 1 5 29 11 0 0 98 (87–100)
Sulfamethoxazole 0 0 5 30 11 0 0 100 (90.4–100)
Trimethoprim 0 0 7 28 11 0 0 100 (90.4–100)
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Discussion
The manufacturer’s guidelines (TREK Diagnostic Sys-
tems, Cleveland, OH) recommend the SLOMYCO Sen-
sititre® method for antibiotic susceptibility testing in M. 
marinum, but studies evaluating the concordance with 
the reference agar dilution method have not been pub-
lished yet. As the SLOMYCO Sensititre® panel technique 
presents several advantages (commercial availability; 
standardization; easy to set up and to interpret; and 
amenable to automation [2, 19] compared to the time-
consuming and cumbersome agar dilution method, our 
objective was to compare the performance of these two 
methods.
The lack of difference between the MICs for the M. 
marinum isolates from infected humans and fish could 
be explained by the fact that most of the clinical sam-
ples were from patients who handled infected fish (from 
aquarium tanks or fish-related work) and, therefore, the 
antibiotic susceptibility profiles of the human isolates 
reflected those of the fish isolates.
Our results show that the reproducibility of the SLO-
MYCO Sensititre® results for the reference strains and 
the M. marinum isolates (from human and fish) was 
very good. All results of the independent tests were 
within the ±1 log2 dilution acceptable level of varia-
tion. Moreover, the level of agreement (±1 log2 dilution) 
between the results (MICs and interpretive categories) 
obtained with the SLOMYCO Sensititre® panel and the 
agar dilution methods was good for most of the antibi-
otics recommended by CLSI and ATS [12] for the treat-
ment of (rifampin, rifabutin, amikacin, clarithromycin 
and sulfamethoxazole–trimethoprim) or with therapeu-
tic potential (linezolid, isoniazid) for M. marinum infec-
tions. It should be noted that two very major errors were 
observed for rifampin in isolates in which the MIC for 
rifampin was just above the breakpoint (2  μg/mL) and 
that still belong to the wild type population [2]. The clini-
cal significance of these data is unclear. Moreover, the 
MIC of the only rifampin-resistant M. marinum reported 
until now [14] was clearly above the breakpoint (>16 µg/
Table 4 Comparison of the MIC values obtained by using the SLOMYCO Sensititre® panel and the agar dilution methods 
for 46 M. marinum isolates
Antimicrobial  
agents
No. of results within log2 concentration difference of % essential agreement 
(confidence interval)
>−2 −2 −1 0 1 2 >2
Amikacin 0 11 34 1 0 0 0 76.1 (70–87)
Ciprofloxacin 0 1 32 11 2 0 0 98 (87–100)
Clarithromycin 4 3 23 15 1 0 0 85 (70.5–93.2)
Doxycycline 0 0 0 0 33 12 1 72 (56.3–83.5)
Ethambutol 12 19 14 1 0 0 0 33 (20–48.1)
Ethionamide 36 9 1 0 0 0 0 2.2 (0.1–13)
Isoniazid 0 6 27 11 2 0 0 87 (73–95)
Linezolid 0 0 10 20 15 1 0 98 (87–100)
Moxifloxacin 0 4 20 18 3 0 1 91.3 (87–100)
Rifabutin 0 0 0 0 35 11 0 76.1 (61–87)
Rifampin 0 11 20 15 0 0 0 76.1 (61–87)
Streptomycin 2 17 22 5 0 0 0 59 (43.3–72.7)
Sulfamethoxazole 2 10 15 13 4 1 1 70 (54.1–82)
Trimethoprim 3 9 26 6 2 0 0 74 (59–85.2)
Table 5 Comparison of  the susceptibility testing results 
(resistance/susceptibility) and category errors (very major 
or major error) by  using the SLOMYCO Sensititre® panel 
(SSPM) and  the agar dilution method (ADM) for  46 M. 
marinum isolates following the CLSI guidelines
SMT–TMP sulfamethoxazole–trimethoprim
Antimicrobial 
agents  
[breakpoints  
(µg/mL)]
% resistant 
ADM
% resistant 
SSPM
Category 
errors (N°)
% agree‑
ment
Amikacin (32) 0 0 None 100
Ciprofloxacin (2) 0 0 None 100
Clarithromycin 
(16)
0 0 None 100
Doxycycline (4) 0 100 Major (46) 0
Ethambutol (4) 2.2 0 Very major (1) 98
Moxifloxacin (2) 0 0 None 100
Rifabutin (2) 0 0 None 100
Rifampin (1) 4.3 0 Very major (2) 96
SMT‑TMP (2/38) 0 0 None 100
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mL). Unfortunately, we could not evaluate the ability 
of the SLOMYCO Sensititre® panel to detect resistant 
strains, because none of the isolates tested in this study 
was considered as antibiotic-resistant.
Conversely, poor agreement was observed for etham-
butol. The MICs for ethambutol obtained with the SLO-
MYCO Sensititre® panel were 2–3 dilutions lower than 
those obtained with the reference method. However, this 
poor agreement resulted in only one very major error, 
when MICs were converted into interpretive categories. 
This discrepancy corresponds to a strain with a MIC just 
above the breakpoint (16 µg/mL) (Table 1).
In the case of doxycycline, no agreement was observed 
between methods resulting in 46 major errors. This could 
be explained by (i) the overestimation of doxycycline 
MICs by the SLOMYCO Sensititre® panel that could be 
due to the medium or pH, and (ii) the fact that the MIC50 
and MIC90 were similar to the breakpoint value. Among 
the antibiotics recommended by CLSI and on the basis 
of in vitro susceptibility testing, our results confirm that 
rifampin, rifabutin, amikacin, clarithromycin and sul-
famethoxazole–trimethoprim are good options for the 
treatment of M. marinum infections, as reported in pre-
vious studies [2, 4, 11, 14, 15, 19]. Sulfamethoxazole and 
trimethoprim showed good in  vitro activity against M. 
marinum and could be considered as an alternative treat-
ment [19]. The present study brings new data on M. mari-
num susceptibility pattern to ethionamide, streptomycin 
and linezolid. The American Thoracic Society recom-
mendations for the treatment of some nontuberculous 
mycobacteria (NTM) infections include the use of strep-
tomycin (for rifampin-resistant M. kansassii infection) 
and ethionamide (for M. malmoense infection) [7, 12]. 
However, the lack of clinical experience in M. marinum 
infections and the absence of breakpoints for NTM sus-
ceptibility and resistance to these two antibiotics did not 
allow predicting their potential efficiency in M. marinum 
infections [16]. Linezolid has been reported to be effective 
against mycobacteria (M. chelonae and M. marinum) [6, 
7] and for treating skin and soft tissue infections [6, 7]. In 
our study, linezolid was one of the most active antimicro-
bial agents in agreement with the low MIC determined in 
a previous study [4]. Despite the lack of breakpoint values 
for M. marinum, linezolid may be an interesting alterna-
tive therapeutic agent due to its pharmacological proper-
ties. This study confirmed that M. marinum is resistant to 
isoniazid and ethambutol [7] and the observed M. mari-
num susceptibility pattern corresponded to the wild type 
phenotype, as previously reported [2, 7, 14, 18, 19]. As the 
ethambutol MIC90 was close to the breakpoint and clear 
evidence on the clinical efficacy of this antibiotic are lack-
ing, it should not be recommended as a first-line drug for 
M. marinum infection treatment.
Conclusion
In this study, we evaluated the SLOMYCO Sensititre® panel 
method for susceptibility testing in 44 M. marinum iso-
lates (from humans and fish) relative to the reference agar 
dilution method. Our results indicate that the SLOMYCO 
Sensititre® panel method could provide a potential alterna-
tive to the reference agar dilution method, when DST in M. 
marinum is required, except for doxycycline. If doxycycline 
susceptibility needs to be tested, the use of another method 
(broth microdilution) is more appropriate.
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